English | Español

Genentech Inc.
Press release submission | Sep 16, 2018

GENENTECH INC: FDA Approves Subcutaneous Formulation of Actemra for Use in Active Systemic Juvenile Idiopathic Arthritis (SJIA), a Rare Form of Juvenile Arthritis

Trending
+ Regulatory
M. Y. Bailey | Aug 7, 2026

PhRMA's Zirkelbach: 340B program has changed dramatically with 'little transparency into how patients benefit'
+ Pharmaceuticals
Patient Daily | Aug 6, 2026

FDA approves Replimune’s melanoma drug Tudriqev after advisory committee debate
Patient Daily reports | Aug 10, 2026

SoCal Breathe Free warns persistent sinus symptoms may signal chronic inflammation
+ Pharmaceuticals
Patient Daily | Aug 7, 2026

Researchers develop computer model linking brain chemistry to neural activity patterns